AI is transforming life sciences but raising risk concerns, new benchmark report finds

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

AI is transforming life sciences but raising risk concerns, new benchmark report finds

Sponsored by

Arnold and Porter logo.png
Arnold & Porter image.jpg

A new survey by Arnold & Porter reveals that AI adoption in life sciences is accelerating, driving innovation in drug discovery, manufacturing, and sales. The report highlights the evolution in the adoption of the technology that needs to be accompanied by good risk assessment and compliance practices

A new report commissioned by Arnold & Porter, based on a survey of 100 senior executives and department heads from biopharmaceutical, digital health, diagnostics, and medical device companies, shows that AI adoption is accelerating across the industry as companies implement it to accelerate product discovery and development, optimise manufacturing and the supply chain, improve marketing and sales strategies, and more.

However, as with any disruptive innovation, risks need to be managed. The report also highlights looming governance and compliance needs as companies seek to mitigate the risks associated with AI technologies, particularly in areas such as data privacy, cybersecurity, and intellectual property.

The Arnold & Porter report found that AI use is still in its early stages for many in the life sciences industry, with around 75% of respondents beginning implementation less than two years ago. Despite this, 86% of companies currently integrating AI plan to fully deploy these tools within the next two years, reflecting a significant acceleration in AI adoption.

R&D leading AI use, with commercial functions close behind

R&D emerged as the leading area of AI implementation, with 79% of respondents actively using, or planning to use, AI to drive faster, more efficient drug discovery and clinical trials. AI is also making inroads into manufacturing (62%), marketing (45%), and regulatory functions (42%) as companies seek to harness the power of AI across the entire product life cycle.

Governance amid rapid AI adoption

Despite AI’s rapid pace, AI governance is an ongoing challenge for many life sciences companies. According to the survey, only 55% of companies currently using AI have implemented formal AI policies or standard operating procedures. Even fewer – just 51% of companies – have completed regular AI audits or assembled cross-functional teams to oversee safe and compliant AI use. This data suggests that companies will need to prioritise risk management and compliance more to realise AI's full potential without exposing themselves to unnecessary vulnerabilities.

AI's impact on product discovery and sales

The survey found that AI already delivers tangible benefits in the product discovery and commercialisation phases. Approximately half of respondents have explored leveraging AI to optimise product discovery and design, citing anticipated faster time to market and improved efficiency as key drivers. Additionally, 85% of respondents reported that AI-driven initiatives to boost commercial effectiveness have been highly productive.

IP concerns loom as AI expands

The survey also uncovered rising concerns over AI-related intellectual property issues. Nearly three-quarters (74%) of respondents expressed significant concern about the potential for AI to introduce new intellectual property challenges within the next year. As AI-driven innovations continue to reshape the industry, life sciences companies are increasingly vigilant about protecting their breakthroughs.

Looking ahead: AI's growing role in life sciences

As AI becomes more embedded in life sciences operations, its role in patient care and diagnostics is expected to grow. The survey suggests that AI-enabled diagnostic tools, clinical trials, and AI-assisted treatment plans will soon become standard across the healthcare industry. However, given that regulators are already signalling heightened scrutiny of AI use from a compliance perspective, companies must address governance gaps to ensure safe, effective, and compliant use as they progress with AI integration.

Arnold & Porter's full report, The Convergence of Life Sciences and Artificial Intelligence: Seizing Opportunities While Managing Risk, can be found here. It also features in-depth analyses of the survey results and additional resources on AI issues in product design and discovery, intellectual property, medical device regulations, clinical development, privacy and cybersecurity, manufacturing and supply chain, commercialisation, payments, governance and compliance, implementation, global considerations, and more.

About Arnold & Porter

Arnold & Porter combines sophisticated regulatory, litigation, and transactional capabilities to resolve clients’ most complex issues. With over 1,000 lawyers practising in 15 offices worldwide, the firm offers deep industry experience and an integrated approach that spans more than 40 practice areas. Through multidisciplinary collaboration and focused industry experience, the firm provides innovative and effective solutions to mitigate risks, address challenges, and achieve successful outcomes.

more from across site and SHARED ros bottom lb

More from across our site

Legacy firm Allen & Overy agreed a high-profile tie-up with US firm Shearman & Sterling in May last year
News of Verizon settling its lawsuit with Headwater Research and a copyright setback for AI firm Perplexity at a New York court were also among the top talking points
IPH, which owns several IP businesses in the APAC and Canada, reported a 16.5% increase in revenue and 13% jump in profit after tax
With Ireland’s government re-engaging with the idea of a UPC referendum, it provides a chance to improve the system further
US-based company says appointment of Jorge Ordonez shows its momentum as a private-equity-backed platform expanding in the IP services market
The firm hired an IP litigation team during the reporting period and has entered the Managing IP rankings for trademark work
Masaki Mikami of Marks IP explains how he helped prove acquired distinctiveness to secure protection for 'Pocky' in Japan
Daralyn Durie discusses the ‘amazing’ opportunity of working on an AI case, the value of celebrating women, and how to build the next wave of talent
New members of the Access Advance patent pool and Harvard University coming under fire were also among the top talking points
Team from Graham Watt & Co will join Beck Greener’s London office
Gift this article